author

Geordie Carragher

Geordie Carragher is a staff writer for Cantech Letter

The Latest From Geordie Carragher

Analysts Cannabis hiti

High Tide is the best idea in Canadian cannabis, says Echelon

Analysts Pharma and Biotech hls

HLS Therapeutics is a screaming Buy right now, says Stifel

Analysts Resource Tech neo

Neo Performance Materials is undervalued, says Paradigm

Analysts Crypto voyg

Confidence in Voyager Digital “significantly eroded,” says Eight Capital

Analysts Cannabis cron

Pot stock Cronos is a Buy, says Raymond James

Analysts Life Sciences DNA

Ginkgo Bioworks has a huge upside, says Raymond James

Analysts IT cts

Converge Technology is a Buy, says Laurentian Bank

Analysts Crypto voyg

Crypto stock Voyager Digital downgraded by Eight Capital

Analysts Hardware bln

Blackline Safety has 70 per cent upside, says Beacon

Analysts IT alya

Good upside potential from Alithya Group, says Echelon

Analysts Cannabis Retail hiti

High Tide keeps “Outperform” rating with ATB Capital

Analysts Cannabis faf

ATB Capital keeps Buy rating on Fire & Flower

Analysts Health sgmd

There’s more upside to Salona Global, says Leede Jones Gable

Analysts Pharma and Biotech vph

iA Capital lowers target on Valeo Pharma

Analysts Retail Software vsby

CNSX:VSBY has a 307 per cent upside, says Echelon

Analysts Gaming brag

BRAGG Gaming keeps $12 target at Eight Capital

Analysts Gaming popr

PopReach has target cut by Eight Capital, still a Buy

Analysts Crypto luxx

Crypto stock Luxxfolio is a Buy, says PI Financial

Analysts LOOP

Loop Industries keeps Buy rating with Paradigm

Analysts gdnp

good natured products is heading back to $1.40, Beacon says

Analysts guru

Guru Organic has a 71 per cent runway, says Laurentian Bank

Analysts Software dtol

D2L keeps Buy rating with Eight Capital

Analysts Health nbly

Neighbourly Pharmacy heading to $40/share, says iA Capital

Analysts Cannabis trul

Tons of upside to Trulieve, says Echelon

Analysts jk

JustKitchen sees price target cut by Beacon Securities

Analysts Cannabis acb

Aurora Cannabis is still a pass, says ATB

Analysts Health qipt

Quipt Home Medical still a Buy, says Leede Jones Gable

Analysts Pharma and Biotech acog

Alpha Cognition has loads of upside, says Raymond James

Analysts Health vhi

VitalHub keeps Buy rating with Beacon Securities

Analysts Gaming popr

PopReach has a 233 per cent upside, says Beacon

Share

Tweet

Share

Get Stock Picks from the Pros. In your Inbox.